Natural History of Treated Neurocysticercosis and Long-Term Outcomes

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Nov 3, 1999

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how to best treat neurocysticercosis, a brain infection caused by a larval stage of the pork tapeworm. Patients often experience symptoms like seizures and headaches, and in more severe cases, they may face issues like chronic headaches or even strokes. The study aims to find out how different treatment methods, including specific medications and anti-inflammatory drugs, affect long-term outcomes for patients with this condition. Researchers will gather information from patients, including health data and samples of blood and urine, to learn more about how these treatments work over time.

If you're between the ages of 3 and 99 and have been diagnosed with neurocysticercosis, you might be eligible to participate in this trial. Participants will need to agree to take part in the study and follow any guidelines provided. By joining, you can help improve our understanding of this disease and how to manage it effectively, which could benefit not only you but also future patients. The trial is currently accepting participants, and there are no specific exclusions based on health status.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• Arms 1-5 (NCC):
• • 1. Aged 3 years and older.
• • 2. Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document.
• • 3. Patients with proven or likely NCC
• Arm 6 (Endemic Exposures):
• • 1. Patient with epidemiologic history compatible with possible exposure to NCC
• • 2. Aged 18 years and older.
• EXCLUSION CRITERIA:
• • Not applicable